IMMUCELL CORP
ImmuCell Corporation (NASDAQ: IMMU) is an animal health biologics company founded in 1982 and operating as a public company since 1987. The company develops, manufactures, and commercializes products designed to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. ImmuCell's… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What IMMUCELL CORP does
In the company’s own words
ImmuCell Corporation (NASDAQ: IMMU) is an animal health biologics company founded in 1982 and operating as a public company since 1987. The company develops, manufactures, and commercializes products designed to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. ImmuCell's website is https://www.immucell.com.
The company's primary product line, First Defense®, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and bioactive components that prevent calf scours, one of the most prevalent diseases in neonatal calves worldwide. First Defense® is administered at or shortly after birth in multiple formats, including single-dose boluses, gel formulations delivered by syringe, and multi-dose powder configurations. The product line includes Dual-Force® and Tri-Shield® branded offerings, which are the only USDA-licensed, orally delivered scours preventives delivering guaranteed doses of pathogen-specific antibodies. First Defense® products represented 99% of total product sales in 2025. The company also offers First Defense Technology® as a bulk powder functional feed ingredient and a California Mastitis Test diagnostic product.
ImmuCell manufactures approximately 4.6 million units annually as of 2025, having significantly expanded capacity from 3 million units in 2023. The company employs 73 people engaged primarily in quality and manufacturing operations, sales and marketing, product development, and finance and administration. Manufacturing operations are concentrated at a single facility in Maine.
Products are marketed through ImmuCell's commercial sales organization in collaboration with a network of international, national, and regional animal health distributors. Approximately 88% of product sales are derived from the U.S. dairy and beef industries, with the majority of sales concentrated among two large distributors. The company estimates the First Defense® product line represents approximately 29% of total market spend in the scours prevention category and protects approximately 15% of calves on preventative programs in the United States.
The company previously invested over $31 million in developing Re-Tain®, an innovative treatment for subclinical mastitis in lactating cows, but paused this initiative in December 2025 to focus resources on the First Defense® franchise and the larger scours market opportunity.
Company details
- Sector
- Materials
- Industry
- Chemicals
- Headquarters
- PORTLAND, ME
- Fiscal year end
- December
- CIK
- 811641
- SIC
- 2835
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns IMMUCELL CORP — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · IMMUCELL CORP’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do IMMUCELL CORP and its peers compare on margins and cash generation over ten years?”
- “Where did five years of IMMUCELL CORP's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in IMMUCELL CORP's last four quarterly filings that the numbers alone won't show?”